Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMNHPOT)

Drug Name

LErafAON Drug Info

Synonyms

RafAON; Antisense raf oligonucleotide, NeoPharm; LErafAON, Insys; LErafAON-ETU; Liposomal antisense therapy, NeoPharm; Cancer therapeutic (antisense), NeoPharm; Liposome encapsulated c-raf antisense oligodeoxynucleotide, NeoPharm; Antisense oligonucleotides (liposome-encapsulated), NeoPharm

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DMNHPOT

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Raf messenger RNA (Raf mRNA)	TTAN5W2	RAF1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Solid tumour/cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Raf messenger RNA (Raf mRNA)	DTT	RAF1	2.12E-04	0.49	2.78

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT00100672) Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer. U.S. National Institutes of Health.
2	Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53.